Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”
A. Lila, L. Alekseeva, I. Belyaeva, I. B. Vinogradova, N. A. Demidova, O. Kalyuzhin, I. I. Nesterovich, V. Sorotskaya, L. Y. Shirokova, S. Yakupova
{"title":"Resolution of the Council of Experts “Results of a multicenter, randomized, double-blind, placebo-controlled study of ARTNEO in patients with stage II–III primary knee osteoarthritis”","authors":"A. Lila, L. Alekseeva, I. Belyaeva, I. B. Vinogradova, N. A. Demidova, O. Kalyuzhin, I. I. Nesterovich, V. Sorotskaya, L. Y. Shirokova, S. Yakupova","doi":"10.14412/1996-7012-2023-6-136-142","DOIUrl":null,"url":null,"abstract":"On August 31,2023 in V.A. Nasonova Research Institute of Rheumatology a meeting of the Expert Council was held at which the principal investigators and co-investigators of the ARTNEO-2021 protocol \"Multicenter randomized double-blind, placebo-controlled study of ARTNEO in patients with stage II-III primary knee osteoarthritis\" was held. A consensus position was developed on the possibility and feasibility of using a combination of undenatured (native) type II collagen, methylsulfonylmethane, boswellic acids, vitamins C and D (ARTNEO complex) in clinical practice. Based on the results of the study, the use of the ARTNEO complex can be recommended as part of a complex therapy for patients with osteoarthritis as a course treatment with total duration up to 6 months. The results of the study can only be interpreted in relation to ARTNEO and cannot be transferred to preparations with a different composition.","PeriodicalId":18651,"journal":{"name":"Modern Rheumatology Journal","volume":"56 16","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14412/1996-7012-2023-6-136-142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
On August 31,2023 in V.A. Nasonova Research Institute of Rheumatology a meeting of the Expert Council was held at which the principal investigators and co-investigators of the ARTNEO-2021 protocol "Multicenter randomized double-blind, placebo-controlled study of ARTNEO in patients with stage II-III primary knee osteoarthritis" was held. A consensus position was developed on the possibility and feasibility of using a combination of undenatured (native) type II collagen, methylsulfonylmethane, boswellic acids, vitamins C and D (ARTNEO complex) in clinical practice. Based on the results of the study, the use of the ARTNEO complex can be recommended as part of a complex therapy for patients with osteoarthritis as a course treatment with total duration up to 6 months. The results of the study can only be interpreted in relation to ARTNEO and cannot be transferred to preparations with a different composition.